|
| Press Releases |
|
 |
|
| Wednesday, August 14, 2024 |
|
|
Sino Biopharmaceutical (1177.HK) Announces 2024 Interim Results |
| Sino Biopharmaceutical Limited (?Sino Biopharmaceutical? or the ?Company?, together with its subsidiaries, the ?Group?) (HKEX:1177), a leading innovation-driven pharmaceutical conglomerate in the PRC, has announced its unaudited interim results for the six months ended 30 June 2024 (the ?Period?). more info >> |
|
| Friday, March 29, 2024 |
|
|
Sino Biopharm (1177.HK) Announces 2023 Annual Results |
| Sino Biopharmaceutical Limited ("Sino Biopharm" or the "Company", together with its subsidiaries, the "Group") (HKEX:1177), a leading innovation-driven pharmaceutical conglomerate in the PRC, has announced its audited financial results for the year ended 31 December 2023. more info >> |
|
| Friday, August 25, 2023 |
|
|
Sino Biopharmaceutical (1177.HK) Announces 2023 Interim Results |
| Sino Biopharmaceutical Limited ("Sino Biopharmaceutical" or the "Company", together with its subsidiaries, the "Group") (HKEX:1177), a leading innovation-driven pharmaceutical conglomerate in the PRC, has announced its unaudited interim results for the six months ended 30 June 2023 (the "Period"). more info >> |
|
| Friday, March 31, 2023 |
|
|
Sino Biopharm (1177.HK) Announces 2022 Annual Results |
| Sino Biopharmaceutical Limited ("Sino Biopharm" or the "Company", together with its subsidiaries, the "Group") (HKEX:1177), a leading innovation-driven pharmaceutical conglomerate in the PRC, has announced its audited financial results for the year ended 31 December 2022. more info >> |
|
| Tuesday, August 23, 2022 |
|
|
Sino Biopharmaceutical (1177.HK) Announces 2022 lnterim Results, Revenue up by 5.9% to RMB15.19 billion |
| Sino Biopharmaceutical Limited ("Sino Biopharmaceutical" or the "Company", together with its subsidiaries, the "Group") (HKEX:1177), a leading innovation-driven pharmaceutical conglomerate in the PRC, has announced its unaudited Interim results for the six months ended 30 June 2022 (the "Period"). more info >> |
|
| Thursday, July 22, 2021 |
|
|
Sino Biopharmaceutical Donates Cash and Supplies Valued at RMB10 Million to Support Henan for Flood Relief and Preventing Epidemic |
| Sino Biopharmaceutical Limited ("Sino Biopharmaceutical" or the "Company", together with its subsidiaries, the "Group") (HKEX:1177), a leading and innovation-driven pharmaceutical conglomerate in the PRC, has announced the donation of cash and supplies valued at RMB10 million to support Henan for flood relief and preventing epidemic. more info >> |
|
| Monday, May 24, 2021 |
|
|
Sino Biopharmaceutical 2021 First Quarterly Profit attributable to Owners of the Parent Soars 118.5% to RMB1.91 Billion |
| Sino Biopharmaceutical Limited ("Sino Biopharmaceutical" or the "Company", together with its subsidiaries, the "Group") (HKEX:1177), a leading and innovation-driven pharmaceutical conglomerate in the PRC, has announced its unaudited first quarterly results for the three months ended 31 March 2021. more info >> |
|
| Tuesday, March 23, 2021 |
|
|
Sino Biopharmaceutical 2020 Net Profit Grows to RMB2.77 Billion amid Adversity |
| Sino Biopharmaceutical Limited ("Sino Biopharmaceutical" or the "Company", together with its subsidiaries, the "Group") (HKEX:1177), a leading and innovation-driven pharmaceutical conglomerate in the PRC, has announced its audited annual results for the year ended 31 December 2020. more info >> |
|
| Monday, December 7, 2020 |
|
|
Sino Biopharm Invests in Sinovac LS, A Leading COVID-19 Vaccine Company in China |
| Sino Biopharmaceutical Limited ("Sino Biopharm" or the "Group"; HKEX: 1177) has announced the investment of US$515 million in Sinovac Life Sciences Co., Ltd. ("Sinovac LS", previously known as Sinovac Research and Development Co., Ltd.), which will be funded by internal resources of the Group and result in a 15.03% equity interest in Sinovac LS. more info >> |
|
| Monday, November 30, 2020 |
|
|
Sino Biopharmaceutical Announces 2020 Third Quarterly Results |
| Sino Biopharmaceutical Limited ("Sino Biopharmaceutical" or the "Company", together with its subsidiaries, the "Group") (HKEX:1177), a leading and innovation-driven pharmaceutical conglomerate in the PRC, more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Unity Scents Launches Revolutionary Oil-Based Perfumes, Challenging Industry Norms
Feb 11, 2025 20:59 HKT/SGT
|
|
|
The First in China! BLA Submitted for Luzhu Biotech's Recombinant Herpes Zoster Vaccine Expected to Be Launched in 2026 
Feb 11, 2025 17:00 HKT/SGT
|
|
|
Venturi Partners invests USD 25M in footwear brand JQR
Feb 11, 2025 10:20 HKT/SGT
|
|
|
Fourth Star's FSTR Token now Available on CoinMarketCap
Feb 10, 2025 23:55 HKT/SGT
|
|
|
An Incredible KLAS Triple-Award Win for AGFA HealthCare!
Feb 10, 2025 22:00 HKT/SGT
|
|
|
GTJAI Participated in First Batch of Northbound Bond Connect Offshore RMB Repurchase Business on Launch Day
Feb 10, 2025 18:58 HKT/SGT
|
|
|
Move Digital Leads AI Revolution in 2025, Expands High-Level Consulting for Family Offices Worldwide
Feb 10, 2025 18:00 HKT/SGT
|
|
|
uSMART Capital, LLC officially approved for U.S. FINRA license
Feb 10, 2025 17:04 HKT/SGT
|
|
|
NEC Solution Modernizes Network Infrastructure Construction Work
Feb 10, 2025 15:05 JST
|
|
|
Renewable Energy Power Purchase Agreements: Analyzing, Structuring, and Negotiating for Bankable Green Investments in Competitive Markets
Feb 10, 2025 13:00 HKT/SGT
|
|
|
Olympus Recognized on CDP's "A List", the Highest Rating in the Field of Climate Change
Feb 10, 2025 11:00 JST
|
|
|
EVCharge Live Thailand 2025 to showcase the future of electric mobility on 26-27 February at BITEC, Bangkok
Feb 10, 2025 09:44 HKT/SGT
|
|
|
foundit Appoints V Suresh as Chief Executive Officer
Feb 10, 2025 09:00 HKT/SGT
|
|
|
Hola Prime Launches Transformative CSR Initiatives to Support Education, Health, and Sustainability
Feb 8, 2025 07:00 HKT/SGT
|
|
|
uSMART Capital, LLC officially approved for U.S. FINRA license
Feb 7, 2025 17:40 JST
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
